- Tower Cold Chain and CRYOPDP partner to expand temperature-controlled solutions for the pharmaceutical supply chain, particularly in clinical research.
- The collaboration offers a wider range of products, including reusable and cryogenic shipping solutions, aiming to enhance sustainability and global accessibility.
Tower Cold Chain and CRYOPDP have announced a strategic partnership to enhance their product range for the pharmaceutical supply chain. The collaboration will offer expanded temperature-controlled solutions, focusing on clinical research and addressing the growing demand for reliable shipment options.
As part of this partnership, Tower Cold Chain will incorporate CRYOPDP’s dry vapor shippers, designed for cryogenic goods, into its portfolio. These shippers maintain temperatures between -196°C and -150°C, providing new options for transporting highly sensitive materials. This addition allows Tower to offer a broader range of passive temperature-controlled containers, catering to different shipment sizes and temperature needs.
In return, CRYOPDP will include Tower’s reusable KTEvolution small box solutions in its offering. These sustainable, passive containers are particularly suited for small payloads and last-mile deliveries, aligning with CRYOPDP’s sustainability goals.
Niall Balfour, CEO of Tower Cold Chain, expressed optimism about the partnership: “We are delighted to announce our collaboration with CRYOPDP, which allows us to expand our product range. This partnership enables Tower to offer sustainable, cryogenic-level solutions to the pharmaceutical supply chain, ultimately helping to improve patient outcomes worldwide.”
Cedric Picaud, CEO of CRYOPDP, added that working with Tower allows the company to meet its sustainability targets: “Together, we can provide pharmaceutical manufacturers with the most comprehensive range of temperature-controlled solutions available.”